				2024 F	PIA DISCLOSURE (in	c. Vaccines Europe)						_
					te of publication: 3r							
-	full Name	HCPs: City of Principal	Country of Principal Practice	Principal Practice Address	Unique country identifier	1	600	tribution to costs of Events		Fee for service and	consultance	
		Practice HCOs: city where registered	Country of Principal Practice	Principal Practice Address	OPTIONAL		Contribution to costs of Events			ree for service and consultancy		
						Donations and Grants to HCDs and	Sponsorship agreements	r	1		Related expenses agreed in	
						POs	with HCOs / third				the fee for service or	
							parties appointed by		Travel & Accommodation		consultancy contract, including	
							HCDs to manage an Event		Inswel & Accommodation		travel & accommodation	
							manage an overs	Registration Fees		Fees excl. VAT	accommonation	
_	INDIVIDUAL NAMED DISCLOSURE - one line -	er NCE (i.e. of transfers of value	during a way for an individual	i HCP will be summed up: itemization should be available for the in	fieldual Recipient or aubility	subadies' constitution only as						
	Andrea Lenartova	Oslo University Hospital	Norway	Kirkevelen 166, 0450 Oslo. Norway	1	N/A	N/A	NA	2257	18500	5550	
						N/A	N/A					
						N/A	N/A					
					1	N/A	N/A	1	1			
						N/A	N/A				<u> </u>	
č					1	N/A	N/A	1	1			
Ę						N/A	N/A					
				OTHER, NOT INCLUDED ABOV	t - where information cann	ot be diclosed on an individual basis j	for legal reasons					
	Aggregate amount attributable to transfers of value to such Recipients					N/A	N/A					
	Number of Recipients in aggregate disclosure					N/A	N/A					
	X of the number of Recipients included in the aggreate disclosure in the total number, by category, of Recipients disclosed					N/A	N/A					
	ancowa											
	ROWVOULE NAMED DECCOSUME -one law per WC (as a) transferred (velue during or year (or an individual bic) with be summed up; termination also (as declined by the individual frequent or public exclusions; consultation and/, as											
	onk Gastrointestinal Cancer Gruppe Sponionhip to support the meeting the 25-26th of April 2024						38.000 NOK					
	Onkologisk Forum Norge	Sponsorship to support the mes										
	Unkoldgisk Forum Norge	sponsorship to support the mee	ting the 21-22th of November 2			32.000 NOK						
ő												
HCOs												
HCOS				OTHER, NOT INCLUDED ABOY	: - where information cann	ot be dicknowd on an individual basis	for legal reasons					
Ŧ	Aggregate amount attributable to transfers of value to su	di Recipienta		other, not included abov	:- where information cann	ot be diclosed on an individual basis j	for legal reasons N/A					
Ŧ	Aggregate amount attributable to transfers of value to su Number of Recipients in aggregate disclosure	Jh Recipients		other, not included abov	: - where information cann							
Ŧ	Number of Recipients in aggregate disclosure % of the number of Recipients included in the aggreate di		ategory, of Recipients	OTHER, NOT INCLUSED ABOV	t - where information cann	N/A	N/A					
Ŧ	Number of Recipients in aggregate disclosure		ategory, of Recipients	OTHER, NOT INCLUED AND	t-where hytermation cana	N/A N/A	N/A N/A					
Ŧ	Number of Recipients in aggregate disclosure % of the number of Recipients included in the aggreate di		ategory, of Recipients	ohelf, kor actuald abov	E-where information cann	N/A N/A	N/A N/A					
Ŧ	Number of Recipients in aggregate disclosure X of the number of Recipients included in the aggreate di disclosed	in the total number, by a			" - where information cann	N/A N/A	N/A N/A					
Ŧ	Number of Recipients in aggregate disclosure X of the number of Recipients included in the aggreate di disclosed	in the total number, by a		entes, kon accord Actor	t - where information cann - where information cann	N/A N/A	N/A N/A					
Ŧ	Number of Recipients in aggregate disclosure X of the number of Recipients included in the aggreate di disclosed	in the total number, by a		sommed up fromsetton should be excluded for the individual factor	avent or public authorities' s	N/A N/A N/A entablishin only, at appropriate)	N/A N/A					
8 H	Nomber of Recipitets in suggraphic discissore 'S' of the number of Recipitets included in the approach of discissed 'Recipited (Recipitets) (State of the State of the State of the State (Recipited) (State of State of the State of the State of the State (Recipited) (State of State of the Sta	cclosure in the total number, by a still transfers of value during a yes			avent or public authorities' s	N/A N/A N/A annultation (only all appropriate) or for defended con an individual basis	N/A N/A N/A					
POS	Number of Recipients in aggregate dischares N of the number of Recipients included in the apprent of disclosed Nucleicode (AAMED DISCLOSURC -one inegene PC) [1, 6 Aggregate amount attributed in to transfer of volume to use	cclosure in the total number, by a still transfers of value during a yes		sommed up fromsetton should be excluded for the individual factor	avent or public authorities' s	N/A N/A N/A N/A environmentation only an experimental of any of home gamma of a productional devices N/A	N/A N/A N/A (or legal reasons N/A					
POS	Number of Receivants in aggregate disclosure Xe of the number of Receivants included in the apprent of disclosed Aggregate annual included in the human of the second	uclasure in the total number, by a al paneles denies during a pay h Recipients	ar for an individual 140 wal de	sommed up fromsetton should be excluded for the individual factor	avent or public authorities' s	N/A N/A N/A N/A consultation only, ai agangoniste) of the diclosed on an individual basis N/A N/A	N/A N/A N/A N/A N/A N/A					
POS	Survival of Responses in aggregate disclosures 24 Of the number of Respiness included in the approach disclosed Notability, NAMED DECLOSING Cores Integrate PO Aggregate amount attributable to Survival of Alater to un Number of Exclosions in Aggregate disclosure 7 Of the number of Polysion include 1 on the aggregate	uclasure in the total number, by a al paneles denies during a pay h Recipients	ar for an individual 140 wal de	sommed up fromsetton should be excluded for the individual factor	avent or public authorities' s	N/A N/A N/A N/A environmentation only an experimental of any of home gamma of a productional devices N/A	N/A N/A N/A (or legal reasons N/A					
POS	Number of Receivants in aggregate disclosure Xe of the number of Receivants included in the apprent of disclosed Aggregate annual included in the human of the second	uclasure in the total number, by a al paneles denies during a pay h Recipients	ar for an individual 140 wal de	sommed up fromsetton should be excluded for the individual factor	avent or public authorities' s	N/A N/A N/A N/A consultation only, ai agangoniste) of the diclosed on an individual basis N/A N/A	N/A N/A N/A N/A N/A N/A					
POS	Survival of Responses in aggregate disclosures 24 Of the number of Respiness included in the approach disclosed Notability, NAMED DECLOSING Cores Integrate PO Aggregate amount attributable to Survival of Alater to un Number of Exclosions in Aggregate disclosure 7 Of the number of Polysion include 1 on the aggregate	uclasure in the total number, by a al paneles denies during a pay h Recipients	ar for an individual 140 wal de	sommed up fromsetton should be excluded for the individual factor	sient or public authoriter' - where information cann	NA N/A N/A Antibiotion (Init adjacement) Antibiotion (Initial Antibiotion (Initial N/A N/A N/A	N/A N/A N/A N/A N/A N/A					
POS	Survival of Responses in aggregate disclosures 24 Of the number of Respiness included in the approach disclosed Notability, NAMED DECLOSING Cores Integrate PO Aggregate amount attributable to Survival of Alater to un Number of Exclosions in Aggregate disclosure 7 Of the number of Polysion include 1 on the aggregate	uclasure in the total number, by a al paneles denies during a pay h Recipients	ar for an individual 140 wal de	anned as terrated back to an interface of the second second second second second second second second second s	avent or public authorities' s	NA N	N/A N/A N/A N/A N/A N/A					Ν/Α